Valneva (NASDAQ:VALN) Sees Unusually-High Trading Volume – Time to Buy?

Shares of Valneva SE Sponsored ADR (NASDAQ:VALN) saw unusually-strong trading volume on Monday . Approximately 52,339 shares changed hands during trading, an increase of 12% from the previous session’s volume of 46,908 shares.The stock last traded at $6.2550 and had previously closed at $6.17.

Analysts Set New Price Targets

Separately, Wall Street Zen lowered Valneva from a “hold” rating to a “sell” rating in a report on Saturday, December 6th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $15.00.

Valneva Stock Performance

The stock has a market cap of $549.81 million, a PE ratio of -4.02 and a beta of 1.80. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.38 and a quick ratio of 1.85. The business has a 50 day moving average price of $9.78 and a two-hundred day moving average price of $9.57.

Valneva (NASDAQ:VALN) last posted its earnings results on Sunday, February 15th. The company reported ($0.68) earnings per share (EPS) for the quarter. Valneva had a negative return on equity of 76.81% and a negative net margin of 67.64%.The business had revenue of $55.92 million during the quarter. As a group, equities research analysts forecast that Valneva SE Sponsored ADR will post 0.13 EPS for the current fiscal year.

Institutional Trading of Valneva

Several large investors have recently added to or reduced their stakes in VALN. Frazier Life Sciences Management L.P. bought a new stake in shares of Valneva during the 2nd quarter valued at about $8,240,000. Marex Group plc bought a new position in shares of Valneva in the second quarter worth approximately $64,000. JPMorgan Chase & Co. purchased a new stake in shares of Valneva during the third quarter valued at approximately $124,000. VSM Wealth Advisory LLC grew its holdings in shares of Valneva by 125.0% during the third quarter. VSM Wealth Advisory LLC now owns 9,000 shares of the company’s stock valued at $110,000 after buying an additional 5,000 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. bought a new stake in shares of Valneva during the fourth quarter valued at approximately $44,000. Institutional investors own 11.39% of the company’s stock.

Valneva Company Profile

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.